SCHEMBL205074

SCHEMBL205074

CCN(CC)S(=O)(=O)c1cccc(Nc2ccc(Br)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.67
MAPT P10636 8/20 0.67
KMT2A Q03164 6/20 0.67
ALDH1A1 P00352 5/20 0.67
MEN1 O00255 5/20 0.67
MAPK1 P28482 2/20 0.67
HSP90AA1 P07900 1/20 0.67
LMNA P02545 7/20 0.57
TSHR P16473 2/20 0.55
KDM4E B2RXH2 1/20 0.52
ATM Q13315 1/20 0.52
GAA P10253 4/20 0.50
XBP1 P17861 1/20 0.50
HTT P42858 1/20 0.50
PAX8 Q06710 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RAB9A P51151 2/20 0.48
POLB P06746 2/20 0.47
NPC1 O15118 1/20 0.46
CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205076 0.85 LMNA (0.58) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL205075 0.80 ALDH1A1 (0.51) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL264279 0.79 ALDH1A1 (0.69) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL2932439 0.75 LMNA (0.70) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL7340955 0.71 KMT2A (0.59) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL9860335 0.71 ALDH1A1 (0.71) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL397214 0.70 MAPT (0.61) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL14376200 0.69 ALDH1A1 (0.69) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL811396 0.69 ALDH1A1 (0.69) SMN1; SMN2MAPTKMT2AALDH1A1MEN1
SCHEMBL9321475 0.69 ALDH1A1 (0.69) SMN1; SMN2MAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 SMN1; SMN2 3252/4885MAPT 2207/4885KMT2A 3476/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 SMN1; SMN2 3252/4885MAPT 2207/4885KMT2A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.